These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 15001610

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Body habitus changes, metabolic abnormalities, osteopenia and cardiovascular risk in patients treated for human immunodeficiency virus infection.
    Cirelli A, Cirelli G, Balsamo G, Masciangelo R, Stasolla A, Marini M.
    Ann Ital Med Int; 2003; 18(4):238-45. PubMed ID: 14971712
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices.
    Tong Q, Sankalé JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK, Hotamisligil GS.
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1559-64. PubMed ID: 12679439
    [Abstract] [Full Text] [Related]

  • 25. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A.
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [Abstract] [Full Text] [Related]

  • 26. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.
    Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper DA, Carr A.
    J Infect Dis; 2009 Dec 01; 200(11):1746-54. PubMed ID: 19874178
    [Abstract] [Full Text] [Related]

  • 27. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
    Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR.
    J Clin Endocrinol Metab; 2007 Apr 01; 92(4):1283-8. PubMed ID: 17227801
    [Abstract] [Full Text] [Related]

  • 28. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution.
    Torriani M, Thomas BJ, Barlow RB, Librizzi J, Dolan S, Grinspoon S.
    J Appl Physiol (1985); 2006 Feb 01; 100(2):609-14. PubMed ID: 16223978
    [Abstract] [Full Text] [Related]

  • 29. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR.
    J Clin Endocrinol Metab; 2012 Jun 01; 97(6):1922-8. PubMed ID: 22419728
    [Abstract] [Full Text] [Related]

  • 30. Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART).
    Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG.
    Eur J Med Res; 2009 Jun 01; 14(2):59-64. PubMed ID: 19258214
    [Abstract] [Full Text] [Related]

  • 31. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.
    McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S.
    Am J Clin Nutr; 2001 Nov 01; 74(5):679-86. PubMed ID: 11684538
    [Abstract] [Full Text] [Related]

  • 32. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
    Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A.
    J Clin Endocrinol Metab; 1996 Nov 01; 81(11):3864-70. PubMed ID: 8923830
    [Abstract] [Full Text] [Related]

  • 33. Prevalence of bone mineral density abnormalities and related risk factors in an ambulatory HIV clinic population.
    Guillemi S, Harris M, Bondy GP, Ng F, Zhang W, Lima VD, Michaels CE, Belzberg A, Montaner JS.
    J Clin Densitom; 2010 Nov 01; 13(4):456-61. PubMed ID: 20663695
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
    Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J.
    HIV Med; 2011 Mar 01; 12(3):157-65. PubMed ID: 20722752
    [Abstract] [Full Text] [Related]

  • 36. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting.
    Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S.
    J Clin Endocrinol Metab; 2001 Aug 01; 86(8):3533-9. PubMed ID: 11502775
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
    Carr A, Miller J, Eisman JA, Cooper DA.
    AIDS; 2001 Apr 13; 15(6):703-9. PubMed ID: 11371684
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM, Soori T, Kheirandish P, Izadyar S, SeyedAlinagh S, Foroughi M, Rostamian A, Mohraz M.
    Acta Med Iran; 2011 Apr 13; 49(7):460-7. PubMed ID: 21960080
    [Abstract] [Full Text] [Related]

  • 40. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy.
    Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, Stracke H, Bretzel RG.
    J Infect; 2003 May 13; 46(4):221-7. PubMed ID: 12799147
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.